Cancer Data Science Pulse

The Cancer Data Science Pulse blog provides insights on trends, policies, initiatives, and innovation in the data science and cancer research communities from professionals dedicated to building a national cancer data ecosystem that enables new discoveries and reduces the burden of cancer.

In 2016, a Blue Ribbon Panel (BRP) was established, as part of the Beau Biden Cancer Moonshot, to make key recommendations that would support the Moonshot goals of accelerating progress in cancer research and breaking down barriers to developing new treatments. The Enhanced

In the past year, the use of Artificial Intelligence (AI) in radiology, also called "radiomics," has been getting a lot of attention, mainly because of the progress Deep Learning (DL) has made from a sub-human performance to performance that is similar, or in some cases superior, to that of humans.

Now is the time for researchers across domains to ideate together, share data, and maximize the utility of those data. This is "the urgency of now" according to former Vice President Joe Biden, who delivered the keynote address to those in attendance at the September 2017 Human Proteome Organization (HUPO) Annual World Congress.

The data science community is awash with "FAIRness." In the past few years, there has been an emerging consensus that scientific data should be archived in open repositories, and that the data should be Findable, Accessible, Interoperable, and Reusable.

I recently joined NCI to help support strategic data sharing and informatics projects within the Center for Biomedical Informatics and Information Technology (CBIIT). Having worked on information management at another Institute for five years and the trans-NIH

Biomedical research is evolving with an increasing emphasis on data science, e.g.,

In recent years, genomics has been described as a big data science on par with the likes of Twitter, YouTube, and the scientific pursuit of understanding the universe.

Precision medicine has quickly moved to the forefront of clinical research and practice, and is particularly pertinent to cancer since cancer is a disease of the genome.

The recent weeks have been momentous as the high-performance computing (HPC) community embraced the challenge of precision medicine.

These days there seems to be a lot of talk about atlases for cancer. Most of us are familiar with The Cancer Genome Atlas (TCGA), the long-running effort which, over the past decade, sequenced genomes from thousands of tumor samples covering dozens of cancer types. TCGA catalogued the complex patterns of gene mutations underlying tumors, implicated numerous new cancer genes, and is generally viewed as a resounding success.